Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Open-label, multi-center, Phase III clinical trial to compare the effectiveness and
tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid
(3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH)
to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including
children and HIV-infected persons, who require treatment of latent TB infection (LTBI).